Medicinal preparations characterised by the non-active ingredients used

Industry

  • CPC
  • A61K47/00
This industry / category may be too specific. Please go to a parent level for more data

Sub Industries

A61K47/02Inorganic compounds A61K47/06Organic compounds A61K47/08containing oxygen A61K47/10Alcohols Phenols Salts thereof A61K47/12Carboxylic acids Salts or anhydrides thereof A61K47/14Esters of carboxylic acids A61K47/16containing nitrogen A61K47/18Amines Quaternary ammonium compounds A61K47/183Amino acids or aminosulphonic acids A61K47/186Quaternary ammonium compounds A61K47/20containing sulfur A61K47/22Heterocyclic compounds A61K47/24containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur A61K47/26Carbohydrates A61K47/28Steroids A61K47/30Macromolecular compounds A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61K47/36Polysaccharides Derivatives thereof A61K47/38Cellulose Derivatives thereof A61K47/40Cyclodextrins Derivatives thereof A61K47/42Proteins Polypeptides Degradation products thereof Derivatives thereof A61K47/44Oils, fats or waxes according to more than one of groups A61K47/02 - A61K47/42; Natural or modified natural oils, fats or waxes, e.g.(polyethoxylated) castor oil, montan wax, ozokerite, lignite, shellac, rosin, beeswax, lanolin A61K47/46Ingredients of undetermined constitution or reaction products thereof A61K47/48the non-active ingredient being chemically bound to the active ingredient A61K47/48007the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent A61K47/48015the modifying agent being an inorganic compound A61K47/48023the modifying agent being an organic compound A61K47/4803the modifying agent being an organic ion that forms an ion pair complex with the pharmacologically or therapeutically active agent A61K47/48038the modifying agent being a carboxylic acid A61K47/48046the modifying agent being a lipid A61K47/48053the modifying agent being a phospholipid A61K47/48061the modifying agent being a heterocyclic compound A61K47/48069the modifying agent being a heterocyclic compound which being a porphyrine or a porphyrine with an expanded ring system A61K47/48076the modifying agent being a chelate, i.e. single central atom/ion sequestered by a polydentate ligand A61K47/48084the modifying agent being a phosphate or phosphonate not being a phospholipid A61K47/48092the modifying agent linked to the pharmacologically or therapeutically active agent being a sugar, nucleoside, nucleotide, nucleic acid A61K47/481the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds A61K47/48107one of the codrug's components being a vitamin A61K47/48115one of the codrug's components being an antibiotic A61K47/48123the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone, bile acid A61K47/4813pretargeting systems involving an organic compound, not being a peptide, protein or antibody, for targeting specific cells A61K47/48138ECTA, enzyme catalyzed therapeutic agent A61K47/48146the modifying agent being biotin A61K47/48153the modifying agent being a chemiluminescent acceptor A61K47/48161Redox delivery systems A61K47/48169the modifying agent being an organic macromolecular compound A61K47/48176the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds A61K47/48184the macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds being an ion exchange resin A61K47/48192the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61K47/482the macromolecule is/contains a polyester A61K47/48207the macromolecule is/contains a polyamide A61K47/48215the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer A61K47/48223the macromolecule contains phosphorus in the main chain A61K47/4823the organic macromolecular compound being a polysaccharide or a derivative A61K47/48238the modifying agent being a protein, peptide, polyamino acid A61K47/48246drug-peptide, protein or polyamino acid conjugates A61K47/48253the peptide, protein or polyamino acid in the drug conjugate being a branched, dendritic or hypercomb peptide A61K47/48261the peptide or protein in the drug conjugate being a toxin or a lectin A61K47/48269the peptide or protein in the drug conjugate being a cytokine A61K47/48276the peptide or protein in the drug conjugate being a receptor as such, e.g. CD4; a cell surface antigen (therefore not a peptide ligand targeting the antigen); a cell surface determinant A61K47/48284the peptide or protein in the drug conjugate being an albumin A61K47/48292the peptide or protein in the drug conjugate being a connective tissue peptide A61K47/483the peptide or protein in the drug conjugate being a transferrin A61K47/48307the peptide or protein in the drug conjugate being a haemoglobin A61K47/48315the peptide or protein in the drug conjugate being a polycationic or polyanionic oligopeptide, polypeptide or polyamino acid A61K47/48323polyanionic oligopeptide, polypeptide or polyamino acid, used to complex nucleic acids being the therapeutic agent A61K47/4833the entire peptide or protein drug conjugate elicits an immune response A61K47/48338peptidic linker, binder, spacer A61K47/48346pretargeting systems involving a peptide or protein for targeting specific cells A61K47/48353pretargeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems A61K47/48361Enzyme prodrug therapy A61K47/48369the modifying part being an antibody, an immunoglobulin, or a fragment thereof A61K47/48376drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent A61K47/48384drug conjugated to an antibody or immunoglobulin A61K47/48392the drug being a vinca alkaloid A61K47/484the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid A61K47/48407the drug being an antibiotic A61K47/48415the drug being a protein or peptide A61K47/48423the drug being a peptidic cytokine A61K47/4843the drug being an enzyme A61K47/48438the drug being a toxin A61K47/48446the drug being a plant toxin A61K47/48453the drug being a plant heterodimeric toxin; chains A or B containing toxins A61K47/48461the drug being ricin (double chain) A61K47/48469the drug being a ribosomal inhibitory protein,(RIP-i or RIP-II) A61K47/48476the drug being ricin A A61K47/48484the drug being a bacterial toxin A61K47/48492the drug being a fungal toxin A61K47/485the drug being a viral toxin A61K47/48507the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site A61K47/48515not used; see subgroups A61K47/48523the antibody being against material from viruses A61K47/4853the antibody being targeting a RNA virus A61K47/48538the antibody being targeting a material from animals or humans A61K47/48546the antibody being targeting a cytokine A61K47/48553the antibody being targeting an hormone, or an hormone-releasing or -inhibiting factor A61K47/48561the antibody being targeting a receptor, a cell surface antigen, a cell surface determinant A61K47/48569the antibody being targeting a determinant of a tumour cell A61K47/48576the tumour determinant being carcino-embryonic antigen A61K47/48584the tumour determinant being from breast cancer cell A61K47/48592the tumour determinant being from lung cancer cell A61K47/486the tumour determinant being from liver or pancreas cancer cell A61K47/48607the tumour determinant being from kidney or bladder cancer cell A61K47/48615the tumour determinant being from stomach or intestines cancer cell A61K47/48623the tumour determinant being from skin, nerves or brain cancer cell A61K47/4863the tumour determinant being from a cell of a blood cancer A61K47/48638the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate A61K47/48646the antibody being targeting an enzyme A61K47/48653the antibody being targeting an immunoglobulin, being an anti-idiotypic antibody A61K47/48661the antibody being a hybrid immunoglobulin A61K47/48669the antibody being an immunoglobulin containing regions, domains, residues from different species A61K47/48676the immunoglobulin has two or more different antigen-binding sites A61K47/48684cluster-antibody conjugates A61K47/48692polymer-drug antibody conjugates A61K47/487the conjugate or the polymer being a starburst, a dendrimer, a cascade A61K47/48707antibody-chelate conjugate wherein the chelate being used for therapeutic purposes A61K47/48715conjugates wherein the antibody being the modifying agent and wherein the linker, binder, spacer confers particular properties to the conjugate A61K47/48723pretargeting systems involving an antibody for targeting specific cells A61K47/4873clearing therapy or enhanced clearance A61K47/48738rescue therapy; agonist-antagonist; antidote; targeted rescue or protection A61K47/48746two or three steps pretargeting systems, wherein an antibody conjugate being used in at least one of the steps; ligand-antiligand therapy A61K47/48753avidin-biotin system wherein at least one avidin- or biotin-conjugated antibody being used in a two- or three-steps pretargeting system A61K47/48761ADEPT A61K47/48769the conjugate being characterized by a special physical or galenical form A61K47/48776forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992 A61K47/48784the form being semi-solid, an ointment, a gel, a hydrogel, a solidifying gel A61K47/48792the form being a colloid, emulsion A61K47/488the form being a micro-emulsion, nano-emulsion or micelle A61K47/48807micelles formed by phospholipids A61K47/48815the form being a liposome A61K47/48823the form being a liposome which being modified on its surface by an antibody A61K47/4883the form being a polymersome A61K47/48838the form being a lipoprotein vesicle A61K47/48846the form being a ribbon, tubule cochleate A61K47/48853the form being a particulate, powder, adsorbate, bead, sphere A61K47/48861the form being an inorganic particle A61K47/48869the form being a micro- or nano-capsule or a micro/nano-bubble A61K47/48876the form being a solid microparticle having no hollow or gas-filled core A61K47/48884the form being a nanoparticle A61K47/48892the material constituting the nanoparticle being a polymer A61K47/489the material constituting the nanoparticle being a polymer obtained by reactions only involving carbon to carbon A61K47/48907the material constituting the nanoparticle being a polymer obtained otherwise than by reactions involving carbon to carbon unsaturated bonds A61K47/48915the polymer being PLGA, PLA or polyglycolic acid A61K47/48923the polymer being a polysaccharide A61K47/4893the form being a granulate or an agglomerate A61K47/48938the form being a pill, tablet, lozenge, capsule A61K47/48946Microcapsules A61K47/48953Nanocapsules; Nanoparticles A61K47/48961the conjugate being in the form of a host-guest, i.e. being an inclusion complex A61K47/48969inclusion being performed with a cyclodextrin A61K47/48976the form being a fibre, textile, slabb, sheet A61K47/48984the form being a plaster, bandage, dressing, patch A61K47/48992the form being a device, kit .

Patents Grantslast 30 patents

Patents Applicationslast 30 patents